publication . Article . Other literature type . 2018

Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus

Hilary Longhurst;
Open Access English
  • Published: 12 Mar 2018 Journal: Frontiers in Medicine, volume 4 (eissn: 2296-858X, Copyright policy)
  • Publisher: Frontiers Media S.A.
Abstract
Acute treatment of hereditary angioedema due to C1 inhibitor deficiency has become widely available in the last ten years and has greatly improved patients’ quality of life. Two plasma-derived C1 inhibitors (Berinert and Cinryze), a recombinant C1 inhibitor (Ruconest/Conestat alpha), a kallikrein inhibitor (Ecallantide) and a bradykinin B2 receptor inhibitor (Icatibant) are all effective. Durably good response is maintained over repeated treatments and several years. All currently available prophylactic agents are associated with breakthrough attacks, therefore an acute treatment plan is essential for every patient. Experience has shown that higher doses of C1 i...
Subjects
free text keywords: Medicine, Review, angioedemas, hereditary, C1 inhibitor, acute therapy, icatibant, ecallantide, recombinant C1 inhibitor, Medicine (General), R5-920, chemistry.chemical_compound, chemistry, Anaphylaxis, medicine.disease, Thrombosis, Adverse effect, Internal medicine, medicine.medical_specialty, Hereditary angioedema, business.industry, business, C1-inhibitor, biology.protein, biology, Kallikrein, medicine.drug
102 references, page 1 of 7

1 Longhurst H Cicardi M. Hereditary angio-oedema. Lancet (2012) 379(9814):474–81.10.1016/S0140-6736(11)60935-5 22305226 [PubMed] [DOI]

2 Zuraw BL Clinical practice. Hereditary angioedema. N Engl J Med (2008) 359(10):1027–36.10.1056/NEJMcp0803977 18768946 [PubMed] [DOI]

3 Christiansen SC Bygum A Banerji A Busse P Li H Lumry W Before and after, the impact of available on-demand treatment for HAE. Allergy Asthma Proc (2015) 36:145–50.10.2500/aap.2015.36.3831 25715243 [OpenAIRE] [PubMed] [DOI]

4 Zanichelli A Mansi M Azin GM Wu MA Periti G Casazza G Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency. Allergy (2015) 70(12):1553–8.10.1111/all.12731 26304015 [OpenAIRE] [PubMed] [DOI]

5 Longhurst H Bygum A. The humanistic, societal, and pharmaco-economic burden of angioedema. Clin Rev Allergy Immunol (2016) 51(2):230–9.10.1007/s12016-016-8575-2 27388236 [OpenAIRE] [PubMed] [DOI]

6 Caballero T Maurer M Longhurst HJ Aberer W Bouillet L Fabien V Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema. J Investig Allergol Clin Immunol (2016) 26(6):383–6.10.18176/jiaci.0102 [OpenAIRE] [DOI]

7 Bork K Staubach P Eckardt AJ Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol (2006) 101(3):619–27.10.1111/j.1572-0241.2006.00492.x 16464219 [OpenAIRE] [PubMed] [DOI]

8 Bork K Hardt J Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol (2012) 130(3):692–7.10.1016/j.jaci.2012.05.055 22841766 [OpenAIRE] [PubMed] [DOI]

9 Bork K Meng G Staubach P Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion (2005) 45(11):1774–84.10.1111/j.1537-2995.2005.00602.x 16271103 [OpenAIRE] [PubMed] [DOI]

10 Bowen T Cicardi M Farkas H Bork K Longhurst HJ Zuraw B International consensus algorithm for the diagnosis, ther apy and management of hereditary angioedema. Allergy Asthma Clin Immunol (2010) 6(1):24 10.1186/1710-1492-6-24 20667127 [OpenAIRE] [PubMed] [DOI]

11 Cicardi M Bork K Caballero T Craig T Li HH Longhurst H Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy (2012) 67(2):147–57.10.1111/j.1398-9995.2011.02751.x 22126399 [PubMed] [DOI]

12 Craig TJ Bewtra AK Hurewitz D Levy R Janss G Jacobson KW Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditar y angioedema attacks. Allergy Asthma Proc (2012) 33(4):354–61.10.2500/aap.2012.33.3589 22856636 [OpenAIRE] [PubMed] [DOI]

13 Craig T Aygören-Pürsün E Bork K Bowen T Boysen H Farkas H WAO guideline for the management of hereditary angioedema. World Allergy Organ J (2012) 5(12):182–99.10.1097/WOX.0b013e318279affa 23282420 [OpenAIRE] [PubMed] [DOI]

14 Longhurst HJ Tarzi MD Ashworth F Bethune C Cale C Dempster J C1 inhibitor deficiency: 2014 United Kingdom consensus document. Clin Exp Immunol (2015) 180(3):475–83.10.1111/cei.12584 25605519 [OpenAIRE] [PubMed] [DOI]

15 Manson AL Price A Dempster J Clinton-Tarestad P Greening C Enti R In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency. Clin Exp Immunol (2013) 173(1):1–7. [OpenAIRE]

102 references, page 1 of 7
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . Other literature type . 2018

Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus

Hilary Longhurst;